TY - JOUR
T1 - Patient-driven discontinuation of tyrosine kinase inhibitors
T2 - Single institution experience
AU - Benjamini, Ohad
AU - Kantarjian, Hagop
AU - Rios, Mary Beth
AU - Jabbour, Elias
AU - O'Brien, Susan
AU - Jain, Preetesh
AU - Cardenas-Turanzas, Marylou
AU - Faderl, Stefan
AU - Garcia-Manero, Guillermo
AU - Ravandi, Farhad
AU - Borthakur, Gautam
AU - Quintas-Cardama, Alfonso
AU - Cortes, Jorge
N1 - Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - With improved outcome for patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), treatment discontinuation has become increasingly attractive to patients. We analyzed the outcomes of patients who chose to discontinue TKI therapy regardless of their ongoing response. Thirty-five patients with chronic phase CML discontinued TKI in complete cytogenetic response. Of them, 51% discontinued due to adverse effects, 23% due to long complete molecular response (CMR) (> 5 years), 9% due to pregnancy and 17% due to financial problems. After TKI discontinuation, patients were followed for a median of 16 months. Among 27 patients (77%) who discontinued TKIs in CMR, 11 (41%) had a molecular relapse after a median of 3.5 months. In univariate analysis we observed that patients with ≥ 64 months of CMR before TKI discontinuation had superior cumulative proportions of sustained CMR and major molecular response (MMR) at 12 months after discontinuation: 88.9% vs. 45.5% (p = 0.02) and 100% vs. 75% (p = 0.05), respectively. Patients treated with high dose imatinib or second generation TKIs had a higher cumulative proportion of sustained MMR at 12 months after discontinuation than patients treated with standard dose imatinib: 100% vs. 72.2% (p = 0.03), respectively. Of the five patients who stopped TKI in MR4.5 (molecular response of 4.5-log reduction) one lost cytogenetic response. All three patients who discontinued TKIs in MMR lost cytogenetic response; one progressed to accelerated phase. Thirteen patients (37%) restarted TKIs after loss of response: 11 improved their response, and for two it is too early to assess. Treatment discontinuation can lead to sustained CMR in some patients, but risk of relapse is higher if patients discontinue TKIs when not in CMR.
AB - With improved outcome for patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), treatment discontinuation has become increasingly attractive to patients. We analyzed the outcomes of patients who chose to discontinue TKI therapy regardless of their ongoing response. Thirty-five patients with chronic phase CML discontinued TKI in complete cytogenetic response. Of them, 51% discontinued due to adverse effects, 23% due to long complete molecular response (CMR) (> 5 years), 9% due to pregnancy and 17% due to financial problems. After TKI discontinuation, patients were followed for a median of 16 months. Among 27 patients (77%) who discontinued TKIs in CMR, 11 (41%) had a molecular relapse after a median of 3.5 months. In univariate analysis we observed that patients with ≥ 64 months of CMR before TKI discontinuation had superior cumulative proportions of sustained CMR and major molecular response (MMR) at 12 months after discontinuation: 88.9% vs. 45.5% (p = 0.02) and 100% vs. 75% (p = 0.05), respectively. Patients treated with high dose imatinib or second generation TKIs had a higher cumulative proportion of sustained MMR at 12 months after discontinuation than patients treated with standard dose imatinib: 100% vs. 72.2% (p = 0.03), respectively. Of the five patients who stopped TKI in MR4.5 (molecular response of 4.5-log reduction) one lost cytogenetic response. All three patients who discontinued TKIs in MMR lost cytogenetic response; one progressed to accelerated phase. Thirteen patients (37%) restarted TKIs after loss of response: 11 improved their response, and for two it is too early to assess. Treatment discontinuation can lead to sustained CMR in some patients, but risk of relapse is higher if patients discontinue TKIs when not in CMR.
KW - CML
KW - Discontinuation
KW - Treatment
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84919445439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919445439&partnerID=8YFLogxK
U2 - 10.3109/10428194.2013.831092
DO - 10.3109/10428194.2013.831092
M3 - Article
C2 - 23927391
AN - SCOPUS:84919445439
SN - 1042-8194
VL - 55
SP - 2879
EP - 2886
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -